Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vyome Holdings, Inc. (HIND : NSDQ)

• Company Description    Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $2.23 Daily Weekly Monthly 20 Day Moving Average: 39,561 shares Shares Outstanding: 7.02 (millions) Market Capitalization: $15.65 (millions) Beta: 1.38 52 Week High: $33.16 52 Week Low: $1.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.33% -6.15% 12 Week -33.63% -38.64% Year To Date -35.17% -40.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Harvard Square One Mifflin Place Suite 400 - Cambridge,MA 02138 USA ph: 973-832-8147 fax: - contact@vyometx.com http://www.vyometx.com

• General Corporate Information    Officers Venkat Nelabhotla - President and Chief Executive Officer Krishna K. Gupta - Chairman Robert Dickey IV - Interim Chief Financial Officer Stash Pomichter - Director Shiladitya Sengupta - Director Peer Information Vyome Holdings, Inc. (GSAC) Vyome Holdings, Inc. (CASIF) Vyome Holdings, Inc. (ALCD.) Vyome Holdings, Inc. (OMNN) Vyome Holdings, Inc. (CGPI.) Vyome Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92943X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 7.02 Most Recent Split Date: 8.00 (0.25:1) Beta: 1.38 Market Capitalization: $15.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.95 Price/Cash Flow: - Price / Sales: 3.73 EPS Growth vs. Year Ago Period: -100.20% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -97.12% vs. Previous Quarter: -% ROE 03/31/26 - -203.92 12/31/25 - -232.01 09/30/25 - -689.40 ROA 03/31/26 - -134.16 12/31/25 - -117.70 09/30/25 - -189.67 Current Ratio 03/31/26 - 4.27 12/31/25 - 1.99 09/30/25 - 1.94 Quick Ratio 03/31/26 - 4.27 12/31/25 - 1.99 09/30/25 - 1.94 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - -270.58 Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - -270.58 Pre-Tax Margin 03/31/26 - -7,263.06 12/31/25 - -3,274.38 09/30/25 - -206.22 Book Value 03/31/26 - 1.15 12/31/25 - 0.67 09/30/25 - 1.07 Inventory Turnover 03/31/26 - 0.11 12/31/25 - 0.08 09/30/25 - -0.70 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©